Monopar Therapeutics (MNPR) Non-Current Assets (2016 - 2026)

Monopar Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $254921.0 in Q4 2025.

• Quarterly Non-Current Assets changed N/A year-over-year to $254921.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $488859.0 (changed N/A YoY) and the FY2025 annual result came in at $254921.0, changed N/A from the prior year.
• Non-Current Assets climbed to $254921.0 in Q4 2025 per MNPR's latest filing, from $106666.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $254921.0 in Q4 2025 and troughed at $9102.0 in Q1 2025.
• A 4-year average of $72803.1 and a median of $68858.0 in 2021 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets increased 22.52% in 2022, then slumped 79.35% in 2023.
• Over 4 years, Non-Current Assets stood at $68858.0 in 2021, then dropped by 11.08% to $61228.0 in 2022, then plunged by 79.35% to $12646.0 in 2023, then jumped by 1915.82% to $254921.0 in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $254921.0, $106666.0, and $118170.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.